Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 983-988

  Nakagawa, Shigeki ^a   Sakamoto, Yasuo ^a,b   Okabe, Hirohisa ^a   Hayashi, Hiromitsu ^a   Hashimoto, Daisuke ^a   Yokoyama, Naomi ^a   Tokunaga, Ryuma ^a   Sakamoto, Keita ^a   Kuroki, Hideyuki ^a   Mima, Kosuke ^a   Beppu, Toru ^a,b   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cell cycle; Cholangiocarcinoma; DZNep; EZH2

Indexed keywords

3 DEAZANEPLANOCIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GEMCITABINE; HISTONE H3; TRANSCRIPTION FACTOR EZH2;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DRUG POTENTIATION; EPIGENETICS; G1 PHASE CELL CYCLE CHECKPOINT; HISTONE METHYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION;

ADENOSINE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DEOXYCYTIDINE; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; POLYCOMB REPRESSIVE COMPLEX 2; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84892426861     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2922     Document Type: Article

References (40)

1. Alpini G, McGill JM and Larusso NF: The pathobiology of biliary epithelia. Hepatology 35: 1256-1268, 2002.
2. Roberts SK, Ludwig J and Larusso NF: The pathobiology of biliary epithelia. Gastroenterology 112: 269-279, 1997.
3. Welzel TM, Graubard BI, El-Serag HB, et al: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 5: 1221-1228, 2007.
4. Shaib YH, El-Serag HB, Nooka AK, et al: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 102: 1016-1021, 2007.
5. Tao LY, He XD, Qu Q, et al: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China. Liver Int 30: 215-221, 2010.
6. Ringrose L and Paro R: Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 38: 413-443, 2004.
7. Sakamoto Y, Watanabe S, Ichimura T, et al: Overlapping roles of the methylated DNA-binding protein MBD1 and polycomb group proteins in transcriptional repression of HOXA genes and heterochromatin foci formation. J Biol Chem 282: 16391-16400, 2007.
8. Sparmann A and van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846-856, 2006.
9. Cao R and Zhang Y: The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14: 155-164, 2004.
10. Simon JA and Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647: 21-29, 2008.
11. Bachmann IM, Halvorsen OJ, Collett K, et al: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273, 2006.
12. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
13. Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003.
14. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K and Yokozaki H: Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97: 484-491, 2006.
15. Wagener N, Macher-Goeppinger S, Pritsch M, et al: Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10: 524, 2010.
16. Takawa M, Masuda K, Kunizaki M, et al: Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102: 1298-1305, 2011.
17. Nakagawa S, Okabe H, Sakamoto Y, et al: Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann Surg Oncol: Jul 26, 2013 (Epub ahead of print).
18. McCabe MT, Graves AP, Ganji G, et al: Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 109: 2989-2994, 2012.
19. Karanikolas BD, Figueiredo ML and Wu L: Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 70: 675-688, 2010.
20. Watanabe H, Soejima K, Yasuda H, et al: Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int 8: 15, 2008.
21. Ougolkov AV, Bilim VN and Billadeau DD: Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 14: 6790-6796, 2008.
22. Wagener N, Holland D, Bulkescher J, et al: The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 123: 1545-1550, 2008.
23. Glazer RI, Hartman KD, Knode MC, et al: 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 135: 688-694, 1986.
24. Tan J, Yang X, Zhuang L, et al: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050-1063, 2007.
25. Hayden A, Johnson PW, Packham G and Crabb SJ: S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat 127: 109-119, 2011.
26. Miranda TB, Cortez CC, Yoo CB, et al: DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8: 1579-1588, 2009.
27. Fiskus W, Wang Y, Sreekumar A, et al: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114: 2733-2743, 2009.
28. Jiang X, Tan J, Li J, et al: DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 13: 529-541, 2008.
29. Suva ML, Riggi N, Janiszewska M, et al: EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69: 9211-9218, 2009.
30. Avan A, Crea F, Paolicchi E, et al: Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Molecular Cancer Ther 11: 1735-1746, 2012.
31. Xu CR, Cole PA, Meyers DJ, Kormish J, Dent S and Zaret KS: Chromatin 'prepattern' and histone modifiers in a fate choice for liver and pancreas. Science 332: 963-966, 2011.
32. Chang CJ, Yang JY, Xia W, et al: EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 19: 86-100, 2011.
33. Chase A and Cross NC: Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613-2618, 2011.
34. Toll AD, Dasgupta A, Potoczek M, et al: Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Human Pathol 41: 1205-1209, 2010.
35. Chen Y, Xie D, Yin Li W, et al: RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo. Cancer Lett 297: 109-116, 2010.
36. Kikuchi J, Takashina T, Kinoshita I, et al: Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 78: 138-143, 2012.
37. Resnitzky D, Hengst L and Reed SI: Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol Cell Biol 15: 4347-4352, 1995.
38. Girard F, Strausfeld U, Fernandez A and Lamb NJ: Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 2067: 1169-1179, 1991.
39. Faris JE and Zhu AX: Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci 19: 326-336, 2012.
40. Thomas MB: Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Oncol Hematol 61: 44-51, 2007.